EGFR-TKI therapy for NSCLC with an EGFR mutation shows a significantly higher response rate, longer progression-free survival, and better quality of life when compared with platinum-doublet chemotherapy[4,5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.